Anderson K. K., Fuhrer R., Malla A. (2013). "There are too many steps before you get to where you need to be": help-seeking by patients with first-episode psychosis, J Ment Health, 22(4), 384-95. En savoir plus.

Anderson K. K., Fuhrer R., Schmitz N., Malla A. (2013). Determinants of negative pathways to care and their impact on service disengagement in first-episode psychosis, Soc Psychiatry Psychiatr Epidemiol, 48(1), 125-36. En savoir plus.

Anderson K. K., Fuhrer R., Wynant W., Abrahamowicz M., Buckeridge D. L., Malla A. (2013). Patterns of health services use prior to a first diagnosis of psychosis: the importance of primary care, Soc Psychiatry Psychiatr Epidemiol, 48(9), 1389-98. En savoir plus.

Badawi G., Page V., Smith K. J., Gariepy G., Malla A., Wang J., Boyer R., Strychar I., Lesage A., Ying Kin N. (2013). Self-rated health: a predictor for the three year incidence of major depression in individuals with Type II diabetes, J Affect Disord, 145(1), 100-5. En savoir plus.

Braehler C., Valiquette L., Holowka D., Malla A., Joober R., Ciampi A., Pawliuk N., King S. (2013). Childhood trauma and dissociation in first-episode psychosis, chronic schizophrenia and community controls, Psychiatry Res, 210(1), 36-42. En savoir plus.

Chue P., Malla A., Bouchard R. H., Lessard S., Ganesan S., Stip E., Johnson S., Chen E., Ahn Y. M., Kim Y. S., Robinson G., Schweikert C., Gendron A., Eriksson H. (2013). The long-term clinical benefit and effectiveness of switching to once-daily quetiapine extended release in patients with schizophrenia, Curr Med Res Opin, 29(3), 227-39. En savoir plus.

Gardner D. M., Murphy A. L., Kutcher S., Beaulieu S., Carandang C., Labelle A., Lalonde P., Malla A., Milliken H., O'Donovan C., Schaffer A., Soni J., Taylor V. H., Williams R. (2013). Evidence review and clinical guidance for the use of ziprasidone in Canada, Ann Gen Psychiatry, 12(1), 1. En savoir plus.

Hovington C.L., Bodnar M., Joober R., Malla A., Lepage M. (2013). Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms, Schizophr Res, 147(2-3), 223-229. En savoir plus.

Iyer S., Banks N., Roy M. A., Tibbo P., Williams R., Manchanda R., Chue P., Malla A. (2013). A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives, Can J Psychiatry, 58(5 Suppl 1), 14S-22S. En savoir plus.

Lal S., Ungar M., Leggo C., Malla A., Frankish J., Suto M. J. (2013). Well-being and engagement in valued activities: experiences of young people with psychosis, OTJR (Thorofare N J), 33(4), 190-7. En savoir plus.

Latimer E., Wynant W., Clark R., Malla A., Moodie E., Tamblyn R., Naidu A. (2013). Underprescribing of Clozapine and Unexplained Variation in Use across Hospitals and Regions in the Canadian Province of Quebec, Clin Schizophr Relat Psychoses, 7(1), 33-41. En savoir plus.

Malla A. (2013). Commentary on "Did Christianity cause schizophrenia?", Transcult Psychiatry, 50(3), 426-9. En savoir plus.

Malla A., Chue P., Jordan G., Stip E., Koczerginski D., Milliken H., Joseph A., Williams R., Adams B., Manchanda R., Oyewumi K., Roy M. A. (2013). An Exploratory Open-Label Randomized Trial Comparing Risperidone Long Acting Injectable (RLAI) with Oral Antipsychotic Medication in the Treatment of Early Psychosis, Clin Schizophr Relat Psychoses, 1-26. En savoir plus.

Malla A., Tibbo P., Chue P., Levy E., Manchanda R., Teehan M., Williams R., Iyer S., Roy M. A. (2013). Long-acting injectable antipsychotics: recommendations for clinicians, Can J Psychiatry, 58(5 Suppl 1), 30S-5S. En savoir plus.

Manchanda R., Chue P., Malla A., Tibbo P., Roy M. A., Williams R., Iyer S., Lutgens D., Banks N. (2013). Long-acting injectable antipsychotics: evidence of effectiveness and use, Can J Psychiatry, 58(5 Suppl 1), 5S-13S. En savoir plus.

Messier L., Elisha B., Schmitz N., Gariepy G., Malla A., Lesage A., Boyer R., Wang J., Strychar I. (2013). Changes in depressive symptoms and changes in lifestyle-related indicators: a 1-year follow-up study among adults with type 2 diabetes in quebec, Canadian Journal of Diabetes, 37(4), 243-8. En savoir plus.

Montreuil T. C., Malla A., Joober R., Belanger C., Lepage M. (2013). Anxiety symptoms severity and short-term clinical outcome in first-episode psychosis, Early Interv Psychiatry, 7(1), 5-11. En savoir plus.

Pira S., Durr G., Pawliuk N., Joober R., Malla A. (2013). Mode of entry to an early intervention service for psychotic disorders: determinants and impact on outcome, Psychiatr Serv, 64(11), 1166-9. En savoir plus.

Pope M. A., Joober R., Malla A. (2013). Diagnostic stability of first-episode psychotic disorders and persistence of comorbid psychiatric disorders over 1 year, Can J Psychiatry, 58(10), 588-94. En savoir plus.

Pruessner M., Bechard-Evans L., Boekestyn L., Iyer S.N., Pruessner J., Malla A. (2013). Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis, Schizophr Res, 146(1-3), 79-86. En savoir plus.